Prognostic Factors Affecting ALS Progression Through Disease Tollgates

Overview

Journal J Neurol

Specialty Neurology

Date 2024 Dec 16

PMID 39680215

Authors

Haoran Wu

F Safa Erenay

Osman Y Ozaltin

Ozden O Dalgic

Mustafa Y Sir

Qi-Ming He

Brian A Crum

Kalyan S Pasupathy

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Understanding factors affecting the timing of critical clinical events in ALS progression.

Methods: We captured ALS progression based on the timing of critical events (tollgates), by augmenting 6366 patients' data from the PRO-ACT database with tollgate-passed information using classification. Time trajectories of passing ALS tollgates after the first visit were derived using Kaplan-Meier analyses. The significant prognostic factors were found using log-rank tests. Decision-tree-based classifications identified significant ALS phenotypes characterized by the list of body segments involved at the first visit.

Results: Standard (e.g., gender and onset type) and tollgate-related (phenotype and initial tollgate level) prognostic factors affect the timing of ALS tollgates. For instance, by the third year after the first visit, 80-100% of bulbar-onset patients vs. 43-48% of limb-onset patients, and 65-73% of females vs. 42-49% of males lost the ability to talk and started using a feeding tube. Compared to the standard factors, tollgate-related factors had a stronger effect on ALS progression. The initial impairment level significantly impacted subsequent ALS progression in a segment while affected segment combinations further characterized progression speed. For instance, patients with normal speech (Tollgate Level 0) at the first visit had less than a 10% likelihood of losing speech within a year, while for patients with Tollgate Level 1 (affected speech), this likelihood varied between 23 and 53% based on additional segment (leg) involvement.

Conclusions: Tollgate- and phenotype-related factors have a strong effect on the timing of ALS tollgates. All factors should be jointly considered to better characterize patient groups with different progression aggressiveness.

References

Morris J . Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases: An Overview. Neurodiagn J. 2015; 55(3):180-94. DOI: 10.1080/21646821.2015.1075181. View

del Aguila M, Longstreth Jr W, McGuire V, Koepsell T, van Belle G . Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003; 60(5):813-9. DOI: 10.1212/01.wnl.0000049472.47709.3b. View

Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner M . The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016; 17(5-6):414-25. PMC: 4950444. DOI: 10.3109/21678421.2016.1140786. View

Ong M, Tan P, Holbrook J . Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS One. 2017; 12(4):e0174925. PMC: 5390993. DOI: 10.1371/journal.pone.0174925. View

Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. DOI: 10.1016/s0022-510x(99)00210-5. View

Roche J, Rojas-Garcia R, Scott K, Scotton W, Ellis C, Burman R . A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012; 135(Pt 3):847-52. PMC: 3286327. DOI: 10.1093/brain/awr351. View

Balendra R, Jones A, Jivraj N, Knights C, Ellis C, Burman R . Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(3-4):279-84. DOI: 10.3109/21678421.2014.897357. View

Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana M . Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002; 59(1):99-103. DOI: 10.1212/wnl.59.1.99. View

Castelnovo V, Canu E, Riva N, Poletti B, Cividini C, Fontana A . Progression of cognitive and behavioral disturbances in motor neuron diseases assessed using standard and computer-based batteries. Amyotroph Lateral Scler Frontotemporal Degener. 2021; 22(3-4):223-236. DOI: 10.1080/21678421.2020.1867179. View

10.

Turner M, Scaber J, Goodfellow J, Lord M, Marsden R, Talbot K . The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci. 2010; 294(1-2):81-5. DOI: 10.1016/j.jns.2010.03.028. View

11.

Tavazzi E, Daberdaku S, Zandona A, Vasta R, Nefussy B, Lunetta C . Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. J Neurol. 2022; 269(7):3858-3878. PMC: 9217910. DOI: 10.1007/s00415-022-11022-0. View

12.

Dalgic O, Erenay F, Pasupathy K, Ozaltin O, Crum B, Sir M . Tollgate-based progression pathways of ALS patients. J Neurol. 2019; 266(3):755-765. DOI: 10.1007/s00415-019-09199-y. View

13.

Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E . The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014; 83(19):1719-25. PMC: 4239834. DOI: 10.1212/WNL.0000000000000951. View

14.

Dalgic O, Wu H, Erenay F, Sir M, Ozaltin O, Crum B . Mapping of critical events in disease progression through binary classification: Application to amyotrophic lateral sclerosis. J Biomed Inform. 2021; 123:103895. DOI: 10.1016/j.jbi.2021.103895. View

15.

Fu W, Simonoff J . Survival trees for interval-censored survival data. Stat Med. 2017; 36(30):4831-4842. DOI: 10.1002/sim.7450. View

17.

Ingre C, Roos P, Piehl F, Kamel F, Fang F . Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015; 7:181-93. PMC: 4334292. DOI: 10.2147/CLEP.S37505. View

18.

Manjaly Z, Scott K, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein L . The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph Lateral Scler. 2010; 11(5):439-42. PMC: 6485484. DOI: 10.3109/17482961003610853. View

19.

Daghlas I, Lever T, Leary E . A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 19(3-4):206-211. DOI: 10.1080/21678421.2017.1418001. View

20.

Chio A, Canosa A, Gallo S, Cammarosano S, Moglia C, Fuda G . ALS clinical trials: do enrolled patients accurately represent the ALS population?. Neurology. 2011; 77(15):1432-7. DOI: 10.1212/WNL.0b013e318232ab9b. View

21.

Tang M, Gao C, Goutman S, Kalinin A, Mukherjee B, Guan Y . Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering. Neuroinformatics. 2018; 17(3):407-421. PMC: 6527505. DOI: 10.1007/s12021-018-9406-9. View